Pacira BioSciences, Inc. (PCRX)
USD 24.97
(1.67%)
USD 24.97
(1.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 41.95 Million USD | 163.72% |
| 2022 | 15.9 Million USD | -62.1% |
| 2021 | 41.98 Million USD | -71.15% |
| 2020 | 145.52 Million USD | 1421.01% |
| 2019 | -11.01 Million USD | -2238.85% |
| 2018 | -471 Thousand USD | 98.89% |
| 2017 | -42.61 Million USD | -12.28% |
| 2016 | -37.94 Million USD | -2144.67% |
| 2015 | 1.85 Million USD | 113.53% |
| 2014 | -13.71 Million USD | 78.54% |
| 2013 | -63.9 Million USD | -22.24% |
| 2012 | -52.28 Million USD | -20.66% |
| 2011 | -43.32 Million USD | -59.59% |
| 2010 | -27.14 Million USD | 14.38% |
| 2009 | -31.7 Million USD | 24.26% |
| 2008 | -41.86 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 18.88 Million USD | 110.34% |
| 2024 Q1 | 8.97 Million USD | -63.9% |
| 2023 Q3 | 10.85 Million USD | -57.85% |
| 2023 Q4 | 24.87 Million USD | 129.05% |
| 2023 FY | 41.95 Million USD | 163.72% |
| 2023 Q2 | 25.76 Million USD | 231.87% |
| 2023 Q1 | -19.53 Million USD | -93.39% |
| 2022 Q4 | -10.1 Million USD | -1357.72% |
| 2022 Q2 | 19.87 Million USD | 191.1% |
| 2022 Q1 | 6.82 Million USD | 233.13% |
| 2022 FY | 15.9 Million USD | -62.1% |
| 2022 Q3 | -693 Thousand USD | -103.49% |
| 2021 Q2 | 19.08 Million USD | 84.02% |
| 2021 Q1 | 10.36 Million USD | -28.56% |
| 2021 Q4 | -5.12 Million USD | -129.04% |
| 2021 Q3 | 17.66 Million USD | -7.45% |
| 2021 FY | 41.98 Million USD | -71.15% |
| 2020 Q1 | 8.15 Million USD | 266.92% |
| 2020 FY | 145.52 Million USD | 1421.01% |
| 2020 Q2 | -7.26 Million USD | -189.09% |
| 2020 Q3 | 130.11 Million USD | 1890.05% |
| 2020 Q4 | 14.51 Million USD | -88.85% |
| 2019 Q4 | -4.88 Million USD | 19.7% |
| 2019 Q2 | 2.73 Million USD | 198.52% |
| 2019 Q3 | -6.08 Million USD | -322.97% |
| 2019 FY | -11.01 Million USD | -2238.85% |
| 2019 Q1 | -2.77 Million USD | -133.45% |
| 2018 Q3 | -640 Thousand USD | -124.96% |
| 2018 Q1 | -10.68 Million USD | -332.43% |
| 2018 FY | -471 Thousand USD | 98.89% |
| 2018 Q4 | 8.28 Million USD | 1394.53% |
| 2018 Q2 | 2.56 Million USD | 124.01% |
| 2017 FY | -42.61 Million USD | -12.28% |
| 2017 Q4 | 4.59 Million USD | 160.48% |
| 2017 Q3 | -7.59 Million USD | 61.52% |
| 2017 Q2 | -19.74 Million USD | 0.62% |
| 2017 Q1 | -19.86 Million USD | -400.03% |
| 2016 Q4 | -3.97 Million USD | 82.07% |
| 2016 Q2 | -7.95 Million USD | -106.49% |
| 2016 Q1 | -3.85 Million USD | -54.28% |
| 2016 FY | -37.94 Million USD | -2144.67% |
| 2016 Q3 | -22.16 Million USD | -178.51% |
| 2015 Q1 | 1.26 Million USD | -78.28% |
| 2015 Q4 | -2.49 Million USD | -180.95% |
| 2015 FY | 1.85 Million USD | 113.53% |
| 2015 Q3 | 3.08 Million USD | 38475.0% |
| 2015 Q2 | 8000.00 USD | -99.37% |
| 2014 Q4 | 5.8 Million USD | 293.14% |
| 2014 FY | -13.71 Million USD | 78.54% |
| 2014 Q3 | -3 Million USD | 40.36% |
| 2014 Q2 | -5.03 Million USD | 56.11% |
| 2014 Q1 | -11.47 Million USD | 4.01% |
| 2013 Q4 | -11.95 Million USD | 19.13% |
| 2013 Q1 | -23.13 Million USD | -41.55% |
| 2013 FY | -63.9 Million USD | -22.24% |
| 2013 Q2 | -14.03 Million USD | 39.36% |
| 2013 Q3 | -14.78 Million USD | -5.37% |
| 2012 Q2 | -8.29 Million USD | 30.25% |
| 2012 Q1 | -11.89 Million USD | 22.17% |
| 2012 Q3 | -15.74 Million USD | -89.79% |
| 2012 Q4 | -16.34 Million USD | -3.82% |
| 2012 FY | -52.28 Million USD | -20.66% |
| 2011 FY | -43.32 Million USD | -59.59% |
| 2011 Q1 | -9.77 Million USD | -38.77% |
| 2011 Q2 | -8.76 Million USD | 10.35% |
| 2011 Q3 | -9.5 Million USD | -8.5% |
| 2011 Q4 | -15.28 Million USD | -60.74% |
| 2010 Q4 | -7.04 Million USD | 10.84% |
| 2010 Q3 | -7.9 Million USD | -15.95% |
| 2010 Q2 | -6.81 Million USD | -26.35% |
| 2010 Q1 | -5.39 Million USD | 39.9% |
| 2010 FY | -27.14 Million USD | 14.38% |
| 2009 Q3 | -6.59 Million USD | 0.0% |
| 2009 Q4 | -8.97 Million USD | -36.09% |
| 2009 FY | -31.7 Million USD | 24.26% |
| 2008 FY | -41.86 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 12.875% |
| Embecta Corp. | 70.4 Million USD | 40.405% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -123.414% |
| Dynavax Technologies Corporation | -6.38 Million USD | 756.676% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 120.05% |
| PainReform Ltd. | -9.34 Million USD | 549.005% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 633.1% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 1031.083% |
| SCYNEXIS, Inc. | 67.04 Million USD | 37.419% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 1454.028% |
| Cosmos Health Inc. | -18.54 Million USD | 326.262% |
| Journey Medical Corporation | -3.85 Million USD | 1188.892% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 1031.083% |
| Safety Shot Inc | -15.08 Million USD | 378.16% |
| Alpha Teknova, Inc. | -36.78 Million USD | 214.07% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 130.038% |
| Bright Green Corporation | -13.12 Million USD | 419.593% |
| Procaps Group, S.A. | 42.54 Million USD | 1.375% |
| Theratechnologies Inc. | -23.95 Million USD | 275.126% |
| Harrow Health, Inc. | -24.41 Million USD | 271.869% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 967.735% |
| Biofrontera Inc. | -20.13 Million USD | 308.41% |
| DURECT Corporation | -27.62 Million USD | 251.879% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -3088.07% |
| Cronos Group Inc. | -73.96 Million USD | 156.724% |
| OptiNose, Inc. | -35.48 Million USD | 218.24% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 104.186% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 199.422% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -75.426% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -748.433% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -26448.253% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 768.146% |
| Radius Health, Inc. | -25.79 Million USD | 262.673% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 780.749% |
| ProPhase Labs, Inc. | -16.78 Million USD | 350.0% |
| Phibro Animal Health Corporation | 2.41 Million USD | -1636.548% |
| Procaps Group S.A. | 42.54 Million USD | 1.375% |
| Alvotech | -551.73 Million USD | 107.604% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 508.202% |
| Viatris Inc. | 54.7 Million USD | 23.3% |
| Rockwell Medical, Inc. | -8.43 Million USD | 597.156% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 364.801% |
| SIGA Technologies, Inc. | 68.06 Million USD | 38.364% |
| Tilray Brands, Inc. | -244.98 Million USD | 117.126% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -249.247% |
| Shineco, Inc. | -22.44 Million USD | 286.89% |
| PetIQ, Inc. | 2.13 Million USD | -1868.794% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 1075.281% |
| Incannex Healthcare Limited | -18.45 Million USD | 327.288% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 83.198% |
| Alimera Sciences, Inc. | -20.13 Million USD | 308.4% |
| Silver Spike Investment Corp. | 7.34 Million USD | -471.586% |
| Assertio Holdings, Inc. | -331.94 Million USD | 112.639% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 736.383% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 613.954% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 334.399% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 309.176% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 126.177% |
| Hempacco Co., Inc. | -13.12 Million USD | 419.631% |
| Talphera, Inc. | -18.39 Million USD | 328.053% |
| Alvotech | -551.73 Million USD | 107.604% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -17.712% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 87.156% |
| Currenc Group, Inc. | -15.3 Million USD | 374.098% |
| Kamada Ltd. | 8.28 Million USD | -406.458% |
| Indivior PLC | 2 Million USD | -1997.75% |
| Evoke Pharma, Inc. | -7.79 Million USD | 638.416% |
| Flora Growth Corp. | -57.03 Million USD | 173.559% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 309.176% |
| Evolus, Inc. | -61.68 Million USD | 168.015% |
| HUTCHMED (China) Limited | 100.78 Million USD | 58.37% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 69.497% |
| Akanda Corp. | -32.27 Million USD | 229.992% |